These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 35149428)

  • 1. Consensus for HER2 alterations testing in non-small-cell lung cancer.
    Ren S; Wang J; Ying J; Mitsudomi T; Lee DH; Wang Z; Chu Q; Mack PC; Cheng Y; Duan J; Fan Y; Han B; Hui Z; Liu A; Liu J; Lu Y; Ma Z; Shi M; Shu Y; Song Q; Song X; Song Y; Wang C; Wang X; Wang Z; Xu Y; Yao Y; Zhang L; Zhao M; Zhu B; Zhang J; Zhou C; Hirsch FR
    ESMO Open; 2022 Feb; 7(1):100395. PubMed ID: 35149428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
    Ai X; Song Z; Jian H; Zhou Z; Chen Z; Yu Y; Li Z; Lu S
    BMC Cancer; 2021 Sep; 21(1):1033. PubMed ID: 34530760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations.
    Riudavets M; Sullivan I; Abdayem P; Planchard D
    ESMO Open; 2021 Oct; 6(5):100260. PubMed ID: 34479034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of Non-Small Cell Lung Cancer with HER2 Alterations].
    Takakura T; Yamamoto N
    Gan To Kagaku Ryoho; 2023 Jul; 50(7):768-772. PubMed ID: 37496218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer.
    Zhang S; Wang W; Xu C; Zhang Y; Cai X; Wang Q; Song Z; Li Z; Yu J; Zhong W; Wang Z; Liu J; Liu A; Li W; Zhan P; Liu H; Lv T; Miao L; Min L; Lin G; Huang L; Yuan J; Jiang Z; Pu X; Rao C; Lv D; Yu Z; Li X; Tang C; Zhou C; Zhang J; Guo H; Chu Q; Meng R; Liu X; Wu J; Zhou J; Zhu Z; Pan W; Dong X; Pang F; Wang K; Yao C; Lin G; Li S; Yang Z; Luo J; Jia H; Nie X; Wang L; Zhu Y; Hu X; Xie Y; Lin X; Cai J; Xia Y; Feng H; Wang L; Du Y; Yao W; Shi X; Niu X; Yuan D; Yao Y; Kang J; Zhang J; Zhang C; Gao W; Huang J; Zhang Y; Sun P; Wang H; Ye M; Wang D; Wang Z; Wan B; Lv D; Yu G; Shi L; Xia Y; Gao F; Zhang X; Xu T; Zhou W; Wang H; Liu Z; Yang N; Wu L; Wang Q; Wang G; Hong Z; Wang J; Fang M; Fang Y; Zhang Y; Song Y; Ma S; Fang W; Lu Y
    Thorac Cancer; 2023 Jan; 14(1):91-104. PubMed ID: 36444143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer.
    Shiraishi A; Oh-Hara T; Takahashi Y; Uchibori K; Nishio M; Katayama R
    Biochem Biophys Res Commun; 2024 Sep; 725():150255. PubMed ID: 38897043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.
    Nützinger J; Bum Lee J; Li Low J; Ling Chia P; Talisa Wijaya S; Chul Cho B; Min Lim S; Soo RA
    Lung Cancer; 2023 Dec; 186():107385. PubMed ID: 37813015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
    Odintsov I; Makarem M; Nishino M; Bachert SE; Zhang T; LoPiccolo J; Paweletz CP; Gokhale PC; Ivanova E; Saldanha A; Rudin CM; Lockwood WW; Ladanyi M; Somwar R; Jänne PA; Sholl LM
    J Thorac Oncol; 2024 May; 19(5):732-748. PubMed ID: 38154514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.
    Suzawa K; Toyooka S; Sakaguchi M; Morita M; Yamamoto H; Tomida S; Ohtsuka T; Watanabe M; Hashida S; Maki Y; Soh J; Asano H; Tsukuda K; Miyoshi S
    Cancer Sci; 2016 Jan; 107(1):45-52. PubMed ID: 26545934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges.
    Yu Y; Yang Y; Li H; Fan Y
    Cancer Treat Rev; 2023 Mar; 114():102520. PubMed ID: 36738637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel treatment approaches for HER2 positive solid tumors (excluding breast cancer).
    Gaye E; Penel N; Lebellec L
    Curr Opin Oncol; 2022 Sep; 34(5):570-574. PubMed ID: 35943440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.
    Torigoe H; Shien K; Takeda T; Yoshioka T; Namba K; Sato H; Suzawa K; Yamamoto H; Soh J; Sakaguchi M; Tomida S; Tsukuda K; Miyoshi S; Toyooka S
    Cancer Sci; 2018 May; 109(5):1493-1502. PubMed ID: 29532558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea.
    Lee K; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Cancer Res Treat; 2020 Jan; 52(1):292-300. PubMed ID: 31345011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The force of HER2 - A druggable target in NSCLC?
    Jebbink M; de Langen AJ; Boelens MC; Monkhorst K; Smit EF
    Cancer Treat Rev; 2020 Jun; 86():101996. PubMed ID: 32135383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer].
    Ren C; Cao H; Zheng J; Sun W; Zhou J
    Zhongguo Fei Ai Za Zhi; 2023 Apr; 26(4):291-302. PubMed ID: 37183644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic
    Yun KM; Bazhenova L
    BMJ Case Rep; 2023 May; 16(5):. PubMed ID: 37156567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab deruxtecan (DS8201) for advanced non-small cell lung cancer with HER2 exon 20 insertion mutation: a case report.
    He X; Hou L; Bai J; Sun C; Wang D; An G
    Anticancer Drugs; 2024 Jan; 35(1):101-108. PubMed ID: 37615532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of targeted therapy in patients with HER2-positive non-small cell lung cancer: A systematic review and meta-analysis.
    Wu HX; Zhuo KQ; Wang K
    Br J Clin Pharmacol; 2022 May; 88(5):2019-2034. PubMed ID: 34820879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
    Wang Y; Jiang T; Qin Z; Jiang J; Wang Q; Yang S; Rivard C; Gao G; Ng TL; Tu MM; Yu H; Ji H; Zhou C; Ren S; Zhang J; Bunn P; Doebele RC; Camidge DR; Hirsch FR
    Ann Oncol; 2019 Mar; 30(3):447-455. PubMed ID: 30596880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.
    Iwama E; Zenke Y; Sugawara S; Daga H; Morise M; Yanagitani N; Sakamoto T; Murakami H; Kishimoto J; Matsumoto S; Nakanishi Y; Goto K; Okamoto I
    Eur J Cancer; 2022 Feb; 162():99-106. PubMed ID: 34959152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.